Abstract - Lifelong Decisions in MS: Addressing Persistence and Progressing Disease

There are approximately 500,000 people in the United States today who suffer from multiple sclerosis. Of those, some 200,000 are currently on disease-modifying therapy. Another 200,000 people who potentially should be treated are not being treated. And 100,000 people who were originally treated with immune-modulating agents have stopped therapy completely.

Learn what clinicians can do to facilitate long-term adherence to the complex therapies involved in modifying MS disease activity.